The firm plans to launch its first test from the lab, a mRNA-based noninvasive confirmatory lung diagnostic, by the end of this year.
Using blood samples from 200 cancer patients, researchers showed that it is possible to find most early cancer cases with targeted error correction sequencing.
The firm is approaching launch of its lung cancer test with new sales hires planned, but saw its Q2 net loss miss the consensus Wall Street estimate.
The ThromboSeq test detected early-stage cancer with 81 percent accuracy and late-stage cancer with 88 percent accuracy.
Both published last month, the studies looked at, respectively, early-stage discovery of lung cancer markers and development of a clinical test for the disease.
Among its business highlights for the quarter, the firm established coverage for the Afirma genomic sequencing classifier by all major insurance plans.
Investigators using droplet digital PCR methods are following cell-free tumor DNA in the blood, looking for patterns coinciding with immunotherapy treatment outcomes.
Asia Genomics will make CellMax's tests, including the CellMax-DNA Genetic Cancer Risk Test Assure and the CellMax-CRC Protect Test, available immediately.
Neon Therapeutics is sponsoring a Phase Ib trial of neoantigen-based vaccines in combination with anti-PD-1 treatment in melanoma, lung cancer, and bladder cancer.
Using the grant funding, the investigators are aiming to advance the precision diagnosis and treatment of lung cancer.
Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.
Popular Mechanics reports that Caltech researchers have built a prototype nanobot using DNA.
The Sacramento Bee writes that direct-to-consumer genetic testing connected a woman to sperm donor-conceived half siblings.
In PLOS this week: gene expression catalog for sheep, viral diversity among respiratory samples from camels, and more.